Inhibiting GLUT-1 expression and PI3K/Akt signalling using apigenin improves the radiosensitivity of laryngeal carcinoma in vivo

Oncology Reports

Volumn 34, Issue 4, 2015, Pages 1805-1814

  Bao, Yang Yang ^a   Zhou, Shui Hong ^a   Lu, Zhong Jie ^a   Fan, Jun ^b   Huang, Ya Ping ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Apigenin; GLUT 1; Laryngeal carcinoma; PI3K Akt signaling; Radiosensitivity; Xenograft

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APIGENIN; GLUCOSE TRANSPORTER 1; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION; IN VITRO STUDY; INTRACELLULAR SIGNALING; LARYNX CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA; CELL HYPOXIA; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LARYNGEAL NEOPLASMS; RADIATION TOLERANCE; TUMOR CELL LINE; X RAY;

ANIMALS; APIGENIN; APOPTOSIS; CARCINOMA; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HUMANS; LARYNGEAL NEOPLASMS; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; RADIATION TOLERANCE; RNA, MESSENGER; X-RAYS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939169180     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4158     Document Type: Article

References (39)

1. Karlsson TR, Al-Azzawe M, Aziz L, Hurman D and Finizia C: Survival outcome depending on different treatment strategies in advanced stages III and IV laryngeal cancers: An audit of data from two European centres. Eur Arch Otorhinolaryngol 271: 547-554, 2014.
2. H aapaniemi A, Koivunen P, Saarilahti K, Kinnunen I, Laranne J, Aaltonen LM, Närkiö M, Lindholm P, Grénman R, Mäkitie A, et al; The Finnish Head and Neck Oncology Working Group: Laryngeal cancer in Finland: A 5-year follow-up study of 366 patients. Head Neck 00: 00-00, 2014.
3. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
4. Nichols AC, Whelan F, Basmaji J, Dhaliwal S, Dowthwaite S, Chapeskie C, Read N, Palma DA, Fung K, Venkatesan V, et al: Ki-67 expression predicts radiotherapy failure in early glottic cancer. J Otolaryngol Head Neck Surg 41: 124-130, 2012.
5. Nix P, Cawkwell L, Patmore H, Greenman J and Stafford N: Bcl-2 expression predicts radiotherapy failure in laryngeal cancer. Br J Cancer 92: 2185-2189, 2005.
6. Yoshida K, Sasaki R, Nishimura H, Okamoto Y, Suzuki Y, Kawabe T, Saito M, Otsuki N, Hayashi Y, Soejima T, et al: Nuclear factor-kappaB expression as a novel marker of radioresistance in early-stage laryngeal cancer. Head Neck 32: 646-655, 2010.
7. Bussink J, van der Kogel AJ and Kaanders JH: Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 9: 288-296, 2008.
8. Jonathan RA, Wijffels KI, Peeters W, de Wilde PC, Marres HA, Merkx MA, Oosterwijk E, van der Kogel AJ and Kaanders JH: The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol 79: 288-297, 2006.
9. H oogsteen IJ, Marres HA, Bussink J, van der Kogel AJ and Kaanders JH: Tumor microenvironment in head and neck squamous cell carcinomas: Predictive value and clinical relevance of hypoxic markers. A review. Head Neck 29: 591-604, 2007.
10. Bussink J, Kaanders JH and van der Kogel AJ: Tumor hypoxia at the micro-regional level: Clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 67: 3-15, 2003.
11. Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, Hunter R, Stratford I and West C: Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 7: 928-934, 2001.
12. Luo XM, Zhou SH and Fan J: Glucose transporter-1 as a new therapeutic target in laryngeal carcinoma. J Int Med Res 38: 1885-1892, 2010.
13. Rademakers SE, Lok J, van der Kogel AJ, Bussink J and Kaanders JH: Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer 11: 167-176, 2011.
14. Zhou SH, Fan J, Chen XM, Cheng KJ and Wang SQ: Inhibition of cell proliferation and glucose uptake in human laryngeal carcinoma cells by antisense oligonucleotides against glucose transporter-1. Head Neck 31: 1624-1633, 2009.
15. Yan SX, Luo XM, Zhou SH, Bao YY, Fan J, Lu ZJ, Liao XB, Huang YP, Wu TT and Wang QY: Effect of antisense oligodeoxynucleotides glucose transporter-1 on enhancement of radiosensitivity of laryngeal carcinoma. Int J Med Sci 10: 1375-1386, 2013.
16. Melstrom LG, Salabat MR, Ding XZ, Milam BM, Strouch M, Pelling JC and Bentrem DJ: Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas 37: 426-431, 2008.
17. Suh HN and Han HJ: Fibronectin-induced VEGF receptor and calcium channel transactivation stimulate GLUT-1 synthesis and trafficking through PPAR? and TC10 in mouse embryonic stem cells. Stem Cell Res (Amst) 10: 371-386, 2013.
18. Zhao K, Yang SY, Zhou SH, Dong MJ, Bao YY and Yao H T: Fluorodeoxyglucose uptake in laryngeal carcinoma is associated with the expression of glucose transporter-1 and hypoxiainducible-factor-1 and the phosphoinositide 3-kinase/protein kinase B pathway. Oncol Lett 7: 984-990, 2014.
19. Gonnella R, Santarelli R, Farina A, Granato M, D'Orazi G, Faggioni A and Cirone M: Kaposi sarcoma associated herpesvirus (KSHV) induces AKT hyperphosphorylation, bortezomib-resistance and GLUT-1 plasma membrane exposure in THP-1 monocytic cell line. J Exp Clin Cancer Res 32: 79, 2013.
20. H eavey S, O'Byrne KJ and Gately K: Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treat Rev 40: 445-456, 2014.
21. Kaidar-Person O, Lai C, Kuten A and Belkacemi Y; AROME: 'The Infinite Maze? of breast cancer, signaling pathways and radioresistance. Breast 22: 411-418, 2013.
22. Ni J, Cozzi P, Hao J, Beretov J, Chang L, Duan W, Shigdar S, Delprado W, Graham P, Bucci J, et al: Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int J Biochem Cell Biol 45: 2736-2748, 2013.
23. Zhuang W, Qin Z and Liang Z: The role of autophagy in sensitizing malignant glioma cells to radiation therapy. Acta Biochim Biophys Sin (Shanghai) 41: 341-351, 2009.
24. Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, Kearsley JH and Li Y: Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis 4: e875, 2013.
25. Carón RW, Yacoub A, Zhu X, Mitchell C, Han SI, Sasazuki T, Shirasawa S, Hagan MP, Grant S and Dent P: H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent. Mol Cancer Ther 4: 243-255, 2005.
26. Kao GD, Jiang Z, Fernandes AM, Gupta AK and Maity A: Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J Biol Chem 282: 21206-21212, 2007.
27. Bao YY, Zhou SH, Fan J and Wang QY: Anticancer mechanism of apigenin and the implications of GLUT-1 expression in head and neck cancers. Future Oncol 9: 1353-1364, 2013.
28. Shukla S, Bhaskaran N, Babcook MA, Fu P, Maclennan GT and Gupta S: Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway. Carcinogenesis 35: 452-460, 2014.
29. Lee WJ, Chen WK, Wang CJ, Lin WL and Tseng TH: Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol Appl Pharmacol 226: 178-191, 2008.
30. Zhu Y, Mao Y, Chen H, Lin Y, Hu Z, Wu J, Xu X, Xu X, Qin J and Xie L: Apigenin promotes apoptosis, inhibits invasion and induces cell cycle arrest of T24 human bladder cancer cells. Cancer Cell Int 13: 54, 2013.
31. Gao AM, Ke ZP, Wang JN, Yang JY, Chen SY and Chen H : Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis 34: 1806-1814, 2013.
32. Xu YY, Wu TT, Zhou SH, Bao YY, Wang QY, Fan J and Huang YP: Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: An in vitro study. Int J Clin Exp Pathol 7: 3938-3947, 2014.
33. Shukla S and Gupta S: Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle 6: 1102-1114, 2007.
34. H uang XQ, Chen X, Xie XX, Zhou Q, Li K, Li S, Shen LF and Su J: Co-expression of CD147 and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous cell carcinoma. Int J Clin Exp Pathol 7: 1651-1666, 2014.
35. Kunkel M, Moergel M, Stockinger M, Jeong JH, Fritz G, Lehr HA and Whiteside TL: Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity. Oral Oncol 43: 796-803, 2007.
36. Doki Y, Takachi K, Ishikawa O, Sasaki Y, Miyashiro I, Ohigashi H, Yano M, Ishihara R, Tsukamoto Y, Nishiyama K, et al: Reduced tumor vessel density and high expression of glucose transporter 1 suggest tumor hypoxia of squamous cell carcinoma of the esophagus surviving after radiotherapy. Surgery 137: 536-544, 2005.
37. Jacobs SR, Herman CE, Maciver NJ, Wofford JA, Wieman HL, Hammen JJ and Rathmell JC: Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent ad independent pathways. J Immunol 180: 4476-4486, 2008.
38. Wieman HL, Wofford JA and Rathmell JC: Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell 18: 1437-1446, 2007.
39. Schuurbiers OC, Kaanders JH, van der Heijden HF, Dekhuijzen RP, Oyen WJ and Bussink J: The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol 4: 761-767, 2009.